CoChat

Evaluating Early Preventive Antipsychotic and Antidepressant Drug Treatment in an Infection-Based Neurodevelopmental Mouse Model of Schizophrenia

Open access
Meyer, U., Spoerri, E., Yee, B. K., Schwarz, M. J., Feldon, J. · 2010 · Schizophrenia Bulletin
Cited by 115

The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.

Abstract

Current pharmacotherapy of schizophrenia remains unsatisfactory with little hope for complete functional restoration in patients once the disease has developed. A preventive approach based on intervention in the prodromal stage of the disease aiming to preserve functional integrity by halting the progress of the disease is therefore extremely attractive. Here, we investigated the effects of preventive antipsychotic or antidepressant drug treatment in a well-established neurodevelopmental mouse model of multiple schizophrenia-related abnormalities. Pregnant mice on gestation day 9 were exposed to the viral mimic polyriboinosinic-polyribocytidylic acid (2 mg/kg, intravenously) or corresponding vehicle treatment, and the resulting offspring from both prenatal treatment conditions were subjected to chronic antipsychotic (haloperidol or clozapine), antidepressant (fluoxetine), or placebo treatment during the periadolescent stage of development. The effects of the preventive pharmacotherapy on behavioral and pharmacological functions were then investigated in adulthood using paradigms relevant to schizophrenia, namely prepulse inhibition, latent inhibition, and sensitivity to psychostimulant drugs. We show that periadolescent treatment with the reference antipsychotic and antidepressant drugs can successfully block the emergence of multiple psychosis-related behavioral and pharmacological abnormalities in subjects predisposed to adult brain pathology by exposure to prenatal immune challenge. At the same time, however, our study reveals numerous negative influences of the early pharmacological intervention on normal behavioral development in control subjects. Hence, even though preventive pharmacotherapy may be beneficial in individuals with predisposition to psychosis-related brain dysfunctions, chronic antipsychotic or antidepressant drug treatment in false-positive subjects is associated with substantial risk for long-term behavioral disturbances in adulthood.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/schbul/sbn131

Cites

13 of 13 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 13 references

Research works printed but not linked: 37

  1. 1996, Schizophrenia Bulletin, 22, 327, 10.1093/schbul/22.2.327 · DOI · Paper page
  2. Cornblatt, 2002, Schizophrenia research, 54, 177, 10.1016/S0920-9964(01)00365-6 · DOI · Paper page
  3. Ruhrmann, 2005, European psychiatry : the journal of the Association of European Psychiatrists, 20, 1, 10.1016/j.eurpsy.2004.11.001 · DOI · Paper page
  4. Woods, 2003, Biological psychiatry, 54, 453, 10.1016/S0006-3223(03)00321-4 · DOI · Paper page
  5. 2007, The British Journal of Psychiatry, 51, s96
  6. McGlashan, 2003, Schizophrenia research, 61, 7, 10.1016/S0920-9964(02)00439-5 · DOI · Paper page
  7. McGlashan, 2006, American Journal of Psychiatry, 163, 790, 10.1176/appi.ajp.163.5.790 · doi:10.1176/appi.ajp.163.5.790 · Paper page
  8. Cornblatt, 2007, The Journal of clinical psychiatry, 68, 546, 10.4088/JCP.v68n0410 · DOI · Paper page
  9. Cornblatt, 2001, Schizophrenia research, 51, 31, 10.1016/S0920-9964(01)00236-5 · DOI
  10. McGlashan, 2001, Schizophrenia research, 51, 47, 10.1016/S0920-9964(01)00238-9 · DOI
  11. 2006, Schizophrenia Bulletin, 32, 166, 10.1093/schbul/sbj007 · DOI · Paper page
  12. Yung, 1998, The British Journal of Psychiatry, 172, 14, 10.1192/S0007125000297602 · DOI · Paper page
  13. BLOCK, 2006, American Journal of Psychiatry, 163, 1838, 10.1176/appi.ajp.163.10.1838 · doi:10.1176/appi.ajp.163.10.1838
  14. Fusar-Poli, 2007, Lancet, 370, 1746, 10.1016/S0140-6736(07)61732-2 · DOI
  15. Lee, 2005, CNS drugs, 19, 193, 10.2165/00023210-200519030-00002 · DOI
  16. Tenn, 2005, Biological psychiatry, 57, 586, 10.1016/j.biopsych.2004.12.013 · DOI
  17. 2003, 3, 289, 10.1016/S1566-2772(03)00089-6 · DOI
  18. Zuckerman, 2003, Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 28, 1778, 10.1038/sj.npp.1300248 · DOI · Paper page
  19. Meyer, 2006, Experimental brain research. Experimentelle Hirnforschung. Exp rimentation c r brale, 173, 243, 10.1007/s00221-006-0419-5 · DOI
  20. Meyer, 2008, Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 33, 441, 10.1038/sj.npp.1301413 · DOI · Paper page
  21. Ozawa, 2006, Biological psychiatry, 59, 546, 10.1016/j.biopsych.2005.07.031 · DOI · Paper page
  22. Laruelle, 1999, Biological psychiatry, 46, 56, 10.1016/S0006-3223(99)00067-0 · DOI · Paper page
  23. Dunstan, 1979, Journal of neural transmission, 44, 187, 10.1007/BF01253062 · doi:10.1007/bf01253062
  24. Yee, 2005, Behavioural brain research, 163, 265, 10.1016/j.bbr.2005.05.013 · DOI
  25. 2001, 156, 234, 10.1007/s002130100810 · DOI · Paper page
  26. 2003, 169, 257, 10.1007/s00213-002-1313-x · DOI · Paper page
  27. 2005, Schizophrenia Bulletin, 31, 139, 10.1093/schbul/sbi005 · DOI · Paper page
  28. 1987, 91, 415, 10.1007/BF00216006 · DOI · Paper page
  29. Lahti, 1995, Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 13, 9, 10.1038/sj.npp.1380271 · DOI · Paper page
  30. DeVane, 1999, Cellular and molecular neurobiology, 19, 443, 10.1023/A:1006934807375 · DOI
  31. 2000, 148, 83, 10.1007/s002130050028 · DOI · Paper page
  32. 2003, Journal of Pharmacology and Experimental Therapeutics, 305, 625, 10.1124/jpet.102.046987 · DOI · Paper page
  33. Perez-Costas, 2008, Journal of neural transmission, 115, 745, 10.1007/s00702-007-0004-5 · DOI
  34. de Oliveira, 1996, Journal of clinical pharmacy and therapeutics, 21, 229, 10.1111/j.1365-2710.1996.tb01143.x · DOI
  35. Brown, 2002, Mental retardation and developmental disabilities research reviews, 8, 51, 10.1002/mrdd.10004 · DOI · Paper page
  36. 2006, Schizophrenia Bulletin, 32, 200, 10.1093/schbul/sbj052 · DOI · Paper page
  37. Patterson, 2007, Science, 318, 576, 10.1126/science.1150196 · DOI · Paper page

Cited by

See all 115

Metadata

Authors
Meyer, U., Spoerri, E., Yee, B. K., Schwarz, M. J., & Feldon, J.
Venue
Schizophrenia Bulletin
Published
2008-10-08
Volume
36
Issue
3
Pages
607-623
ISSN
  • 0586-7614 (ISSN-L)
  • 1745-1701
OpenAlex
W2171206543
Cited by
115
References
13
FWCI
5.22
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Evaluating Early Preventive Antipsychotic and Antidepressant Drug Treatment in an Infection-Based Neurodevelopmental Mouse Model of Schizophrenia. https://app.cochat.ai/papers/10.1093/schbul/sbn131
The paper
Meyer, U., Spoerri, E., Yee, B. K., Schwarz, M. J., & Feldon, J. (2010). Evaluating Early Preventive Antipsychotic and Antidepressant Drug Treatment in an Infection-Based Neurodevelopmental Mouse Model of Schizophrenia. Schizophrenia Bulletin. https://doi.org/10.1093/schbul/sbn131

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.